-
EOFlow Initiates Eco-Friendly Disposal Campaign for EOPatch in Korea Embracing and Integrating Environmental, Social, and Governance (ESG)
▶EOFlow will collect, process, and dispose of used EOPatch pumps in an environmentally safe manner ▶EOFlow will set up an Incentive Program for this Campaign EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, announced today that the Company is initiating an environmentally friendly disposal campaign to minimize the impact of used EOPatch pumps on the environment. As there are no environmental regulations or guidelines for proper disposal of used medical devices in Korea, used patc...Nov. 09. 2021 -
EOFlow to Raise 100 Billion Korean Won and Offer Stock Split Capital Raised Will Be Used For Global Market Expansion
▶ 100 billion Won to be raised with new common stock offering, to be followed by a 2:1 stock split EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that the Company will raise some 100 billion Won with new common stock offering, after which it will do a 2:1 stock split. The Company will make a new public offering of its common stocks. The company will issue up to 3,000,000 shares of common stocks, representing 25.99% of the current total number of issued shares. The...Oct. 28. 2021 -
EOFlow and Sinocare Establish a Joint Venture Company
▶ Sinocare is China’s Largest Diabetes Management Instrument Manufacturer ▶ Joint venture company to launch a full-scale effort for clinical study to obtain regulatory approval for EOPatch manufacturing and distribution in China ▶ High growth expected from EOPatch business in China where world’s largest diabetes population live EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that the Company will establish a joint venture company “SINOFLOW Co., Ltd...Oct. 27. 2021 -
EOFlow Begins Clinical Study of its Wearable Insulin Pump “EOPatch” on People With Type 2 diabetes in Korea
▶ This clinical study involves ten leading university hospitals and up to one hundred and thirty-six people with Type 2 diabetes. It is Korea’s largest ever clinical study employing insulin pumps. ▶ This pioneering study aims to demonstrate and validate efficacy of EOPatch for Type 2 diabetes therapy. EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that the Company completed enrollment of first patient in a clinical study on type 2 diabetes for its wearable in...Oct. 14. 2021 -
EOFlow Completes its First Shipment to Europe
▶ EOFlow’s European exclusive distributing partner Menarini to showcase the EOPatch at EASD 2021 EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has made its first shipment to Europe today. After launching the wearable insulin pump in Korea this March and obtaining the CE certification in May, EOFlow is now expanding its reach to Europe, starting with the first shipment completed on September 30. EOFlow officially launched its EOPatch, Korea’s first (and the w...Sep. 30. 2021 -
EOPatch awarded GD (Good Design) designation
EOFLOW's wearable disposable insulin pump product, EOPatch, was recently awarded the highly selective Good Design (GD) designation. Hosted annually by Korea Institute of Design Promotion (KIDP) and sponsored by the Korean Ministry of Trade, Industry & Energy (MOTIE), the GD Selection is subject to highly competitive selection processes, and the designation is yet another validation of the excellence of the design and usability of EOPatch. The picture below is EOPatch on display during the Sele...Dec. 13. 2017 -
Luis Malave joins as new president of EOFLOW
Mr. Luis Malave, a long-time industry insider who has contributed significantly to the emergence of the smart insulin patch pump industry, has joined EOFLOW as the new president. Luis was one of the earliest employees at Insulet and was the COO of the company at the time he left. He was also an early member of MiniMed. Prior to this, he also worked at Medtronic and University of Minnesota.Oct. 17. 2017 -
Dr. David Klonoff joins as a Scientific Advisory Board member
EOFLOW announces that David Klonoff, M.D. has joined EOFLOW as the latest member of its Scientific Advisory Board. Dr. Klonoff is Medical Director of the Dorothy L. and James E. Frank Diabetes Research Institute of Mills-Peninsula Medical Center in San Mateo, California and a Clinical Professor of Medicine at UCSF. He has been a Principal Investigator on 110 clinical trials of diabetes drugs and devices, and has been lead investigator on multicenter trials for Novo, Sanofi, Diasome, and Medtronic. He was the lead investigator for th...Oct. 16. 2017 -
Dr. Jonathan Woo joins EOFLOW as CSO
EOFLOW announces that Dr. Jonathan Woo has joined the company as the Chief Strategy Officer. Jonathan was the CEO and Co-Founder of Precursor Energetics, where he launched and managed a Silicon-valley venture-funded advanced material-design company in clean-tech area focusing on printable CIGS solar cell, thin-film Li-ion battery, and wearable/flexible thin-film-transistor display products using printed-electronics processes. He was the CTO and Co-Founder of Nanostellar, working in the area of nano-material design and development for auto...Oct. 13. 2017 -
Luis Malave joins as a new board member of EOFLOW
EOFLOW announces that Luis Malave, a long time industry insider, has formally joined as a new board member as of October 1, 2017. Luis was one of the earliest employees at Insulet and was the COO of the company at the time he left. He was also an early member of MiniMed. Prior to this, he also worked at Medtronic and University of Minnesota.Oct. 12. 2017 -
EOFLOW signs up HUONS as distribution partner for Korea
EOFLOW and Huons (www.huons.com) signed an agreement to appoint Huons an exclusive distributor in the Korean market for EOFLOW's disposable wearable insulin pump solution, EOPatch. Huons is one of the fastest growing pharmaceutical companies in Korea. "We are excited that EOPatch will allow many diabetic patients and their families better manage the disease and improve their quality of life," says Mr. Um, Key An, the president of Huons. You can read about more details from other news sites below (in Korean...Sep. 07. 2017 -
EOFLOW sets up a US subsidiary
EOFLOW is announcing the establishment of EOFLOW, INC., a wholly owned subsidiary of EOFLOW Co., Ltd., in the heart of Silicon Valley, San Jose. The new subsidiary will be largely responsible for the global marketing operations of the whole EOFLOW. It is currently manned by some well-experienced and highly respected industry insiders whose names will be released later at opportune times.Sep. 04. 2017 -
EOFLOW will be at the 2017 EASD, Lisbon (9/11-15)
EOFLOW will exhibit its commercial EOPatch wearable disposable insulin delivery product at the 2017 53rd EASD (European Association for the Study of Diabetes) held in Lisbon, Portugal, 9/11 - 9/15/2017. EOFLOW's booth is E.05. The company recently made its first submission for a regulatory approval of the patch pump product in Korea. Please contact us in advance if you'd like to arrange a meeting with our marketing team: info@eoflow.comAug. 21. 2017 -
EOPatch submitted for KFDS regulatory approval
EOFLOW recently applied for the regulatory approval of its first commercial product, EOPatch, with KFDS (Korean Food and Drug Safety). EOPatch is made up of a wearable disposable insulin pump patch ('Patch'), a smart-phone like controller ('ADM: Advanced Diabetes Manager'), and a management software that runs on a computer ('DDM: Diabetes Data Manager').Aug. 21. 2017 -
EOFLOW featured in a magazine
EOFLOW was featured in a magazine published by SNUHB (Seoul National Hospital - Bundang). SNUH is widely considered one of the best hospitals in Korea, and EOFLOW is currently headquartered in Healthcare Innovation Park owned and managed by SNUH, which hosts scores of promising and outperforming biomedical companies large and small that the hospital sees strategic fit with.Aug. 14. 2017
Healthcare Innovation Park #H2202 Dolma-ro 172 Bundang-gu Seongnam-si Gyeonggi-do Republic of Korea
T (+82) 031-738-0200
F (+82) 031-738-0208
COPYRIGHT ⓒ 2017 EOFLOW CO., LTD. All Rights Reserved.
